

Agence nationale de sécurité du médicament et des produits de santé

CERTIFICATE NUMBER: **2019/HPF/FR/011**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:

The manufacturer: **ELAIAPHARM**

Site address: **2881 route des Crêtes, ZI les Bouillides Sophia Antipolis, VALBONNE, 06560, France**

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **M 18/219** in accordance with Art. 40 of Directive 2001/83/EC transposed in the following national legislation:

Art. L.5124-3 of Public Health Code

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2018-06-29**, it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

1 MANUFACTURING OPERATIONS

1.1	Sterile products
	<i>1.1.1 Aseptically prepared (processing operations for the following dosage forms)</i> 1.1.1.2 Lyophilisates 1.1.1.4 Small volume liquids
	<i>1.1.2 Terminally Sterilised (processing operations for the following dosage forms)</i> 1.1.2.3 Small volume liquids
	<i>1.1.3 Batch certification</i>
1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.8 Other solid dosage forms: granules(en) 1.2.1.13 Tablets
	<i>1.2.2 Batch certification</i>
1.5	Packaging
	<i>1.5.1 Primary Packing</i> 1.5.1.8 Other solid dosage forms: granules(en) 1.5.1.13 Tablets
	<i>1.5.2 Secondary packing</i>
1.6	Quality control testing
	<i>1.6.1 Microbiological: sterility</i> <i>1.6.2 Microbiological: non-sterility</i> <i>1.6.3 Chemical/Physical</i>

2 IMPORTATION OF MEDICINAL PRODUCTS

2.3	Other importation activities
	<i>2.3.2 Importation of intermediate which undergoes further processing</i>

Clarifying remarks (for public users)

Manufacturer (Article R.5124-2 1° of the French Public Health Code) --- Importer (Article R.5124-2 2° of the French Public Health Code) --- Signatory: Mrs Dominique Debourges, deputy head of pharmaceutical product inspection and counterfeiting fight department. The ANSM does not issue hard copy of this authorisation.

2019-01-10

Name and signature of the authorised person of the
Competent Authority of France

Confidential
French National Agency for Medicines and Health
Products Safety
Tel: ***Confidential***
Fax: ***Confidential***